Navigation Links
Fertility experts present the latest research at reproductive medicine meeting
Date:11/7/2008

NEW YORK (Nov. 7, 2008) -- Leading fertility experts at NewYork-Presbyterian Hospital/Columbia University Medical Center are presenting new research findings at the 64th annual American Society of Reproductive Medicine (ASRM) meeting in San Francisco, Nov. 8. Highlights include the following:

  • Dr. Mark V. Sauer is chairing the invited symposia, "Management of the HIV-Discordant Couple Seeking Fertility Care." He will speak on "Clinical Paradigms Gained From 10 Years of Experience."
  • Dr. Rogerio A. Lobo is chairing a plenary session on infertility in polycystic ovary syndrome (PCOS). He will speak on "Management of Infertility in PCOS."
  • Successful Fertility Treatment for HIV Women. "A Systematic, Multidisciplinary Approach to Address the Reproductive Needs of HIV-Seropositive Women" by Drs. Nataki C. Douglas, Bo Yu, Jeffrey Wang, Sreedhar Gaddipati, Michael Guarnaccia and Mark V. Sauer.
    Nearly 130,000 American women are HIV-positive. Most are of reproductive age and many desire children. The researchers sought to establish a comprehensive program to address their fertility needs in order to minimize infectious, medical and reproductive risks to prospective patients. They found that by using a multidisciplinary approach to care, HIV-seropositive women may be successfully managed in a program of assisted reproduction. Of 17 HIV-positive women undergoing IVF, there were seven pregnancies, and five singletons and two sets of twins were delivered by Caesarean section. Throughout the pregnancies, maternal HIV-1 RNA levels remained undetectable and CD4 counts were stable. All infants, tested at birth and at 3 and 6 months of age, remained HIV-negative.
  • SC Ovidrel Can Be Reliably Used for Egg-Cell Donation. "Lower Serum hCG Levels After Ovidrel Administration Do Not Reflect Compromised Oocyte Maturation in Donor Oocyte IVF Cycles," by Drs. Nataki C. Douglas, Bo Yu, Jeffrey Wang, Gary Nakhuda, Mark V. Sauer and Melvin Thornton II.
    Human chorionic gonadotropin (hCG) is used to promote final oocyte (egg cell) maturation for IVF. For ease of administration and improved patient tolerance, use of subcutaneous (SC) Ovidrel instead of intramuscular (IM) u-hCG has been used in women undergoing egg retrieval for oocyte donation. However, a decrease in serum hCG levels, a measure of patient compliance with the drug therapy, was noted after Ovidrel self-administration. The researchers conducted a retrospective cohort study to determine if the lower hCG levels associated with Ovidrel were associated with any measurable detrimental effects on the oocytes or resulting embryos. They found that Ovidrel injection resulted in significantly lower serum hCG levels compared to u-hCG and these levels did not correlate with BMI. And, despite lower serum hCG levels, all clinical outcome parameters were statistically identical. Thus, SC Ovidrel can be reliably used for oocyte donation.
  • Good News for Female Cancer Patients Seeking to Save Their Eggs. "Favorable Clinical Outcomes Attained in Young Cancer Patients Undergoing Oncofertility Treatments" by Drs. Bo Yu, Nataki C. Douglas, Janet Choi and Mark V. Sauer.
    Cancer is commonly diagnosed in women of reproductive age who may desire to freeze (cryopreserve) their eggs or embryos prior to undergoing chemotherapy, radiation or extirpative surgery. The researchers compared the clinical outcomes of cancer patients undergoing egg retrieval with age-matched controls, in order to ascertain if their underlying illness affected their reproductive performance. They found that cancer patients experienced a reasonable response to ovulation induction and as a result, had similar mature oocytes harvested as age-matched controls. The fertilization rate was comparable to controls and all patients successfully achieved embryos or oocytes for cryopreservation despite their illness and the requisite expedited approach to care. Therefore, female patients with cancer should be encouraged to have MIS (Mllerian Inhibiting Substance) assessment, and when their reproductive profile is favorable, be considered for embryo or oocyte cryopreservation in order to maximize opportunity for future fertility before undergoing gonadotoxic treatments.
  • Pregnancy Possible in Breast Cancer Patients After Chemotherapy. "Dissociation of Mllerian Inhibiting Substance (MIS) and Estradiol (E2) Levels After Chemotherapy in Young Women With Breast Cancer" by Drs. Bo Yu, Dawn L. Hershman, Michel J. Ferin, Nataki Douglas, Gary S. Nakhuda and Rogerio A. Lobo.
    The goal of the study was to evaluate the effect of chemotherapy on ovarian function in young women with breast cancer, assessing a marker of ovarian reserve, MIS, as well as E2, Follicle Stimulating Hormone (FSH) and menstrual status. Chemotherapy decreases ovarian reserve rapidly and dramatically as reflected by levels of MIS. After chemotherapy, although E2 levels recover quickly, with 58 percent of women regaining menstrual function by 52 weeks, all MIS levels remain below the normal range of age-matched fertile women. In spite of the concern of reduced fertility six months after chemotherapy, reflected by very low MIS levels, researchers have documented that pregnancy can occur.

'/>"/>
Contact: Belinda Mager
bem9048@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Technique Preserves Future Fertility in Girls With Cancer
2. The American Fertility Association Announces Plan to Help Young Women Preserve Fertility
3. Infertility Survivor Creates Symbolic Pendant to Honor the Journey.
4. Lower Cost Minimal Stimulation IVF Being Performed by Virginia Fertility Doctor, Suheil Muasher
5. Web Site Helps Cancer Patients With Fertility Preservation
6. Brain Master Switch May Control Appetite, Fertility
7. Assisted Fertilization Risks May Be Due to Infertility
8. California Supreme Court Gay-Marriage Ruling Reinforces Top Bay Area Fertility Specialists Support for Same-Sex Couples
9. Simple Procedure Improves Male Fertility
10. Minimally Invasive Treatment Improves Male Fertility
11. Minimally invasive treatment improves male fertility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: